Artificial intelligence using deep learning to screen for referable and vision-threatening diabetic retinopathy in Africa: a clinical validation study

Artificial intelligence for early detection of diabetes mellitus complications via retinal imaging

Background

Diabetes mellitus (DM) increases the risk of vascular complications, and retinal vasculature imaging serves as a valuable indicator of both microvascular and macrovascular health. Moreover, artificial intelligence (AI)-enabled systems developed for high-throughput detection of diabetic retinopathy (DR) using digitized retinal images have become clinically adopted. This study reviews AI applications using retinal images for DM-related complications, highlighting advancements beyond DR screening, diagnosis, and prognosis, and addresses implementation challenges, such as ethics, data privacy, equitable access, and explainability.

Methods

We conducted a thorough literature search across several databases, including PubMed, Scopus, and Web of Science, focusing on studies involving diabetes, the retina, and artificial intelligence. We reviewed the original research based on their methodology, AI algorithms, data processing techniques, and validation procedures to ensure a detailed analysis of AI applications in diabetic retinal imaging.

Results

Retinal images can be used to diagnose DM complications including DR, neuropathy, nephropathy, and atherosclerotic cardiovascular disease, as well as to predict the risk of cardiovascular events. Beyond DR screening, AI integration also offers significant potential to address the challenges in the comprehensive care of patients with DM.

Conclusion

With the ability to evaluate the patient's health status in relation to DM complications as well as risk prognostication of future cardiovascular complications, AI-assisted retinal image analysis has the potential to become a central tool for modern personalized medicine in patients with DM.

The evolution of diabetic retinopathy screening

Diabetic retinopathy (DR) is a leading cause of preventable blindness and has emerged as a global health challenge, necessitating the development of robust management strategies. As DR prevalence continues to rise, advancements in screening methods have become increasingly critical for timely detection and intervention. This review examines three key advancements in DR screening: a shift from specialist to generalist approach, the adoption of telemedicine strategies for expanded access and enhanced efficiency, and the integration of artificial intelligence (AI). In particular, AI offers unprecedented benefits in the form of sustainability and scalability for not only DR screening but other aspects of eye health and the medical field as a whole. Though there remain barriers to address, AI holds vast potential for reshaping DR screening and significantly improving patient outcomes globally.

AI explainability in oculomics: How it works, its role in establishing trust, and what still needs to be addressed

Recent developments in artificial intelligence (AI) have seen a proliferation of algorithms that are now capable of predicting a range of systemic diseases from retinal images. Unlike traditional retinal disease detection AI models which are trained on well-recognised retinal biomarkers, systemic disease detection or "oculomics" models use a range of often poorly characterised retinal biomarkers to arrive at their predictions. As the retinal phenotype that oculomics models use may not be intuitive, clinicians have to rely on the developers' explanations of how these algorithms work in order to understand them. The discipline of understanding how AI algorithms work employs two similar but distinct terms: Explainable AI and Interpretable AI (iAI). Explainable AI describes the holistic functioning of an AI system, including its impact and potential biases. Interpretable AI concentrates solely on examining and understanding the workings of the AI algorithm itself. iAI tools are therefore what the clinician must rely on if they are to understand how the algorithm works and whether its predictions are reliable. The iAI tools that developers use can be delineated into two broad categories: Intrinsic methods that improve transparency through architectural changes and post-hoc methods that explain trained models via external algorithms. Currently post-hoc methods, class activation maps in particular, are far more widely used than other techniques but they have their limitations especially when applied to oculomics AI models. Aimed at clinicians, we examine how the key iAI methods work, what they are designed to do and what their limitations are when applied to oculomics AI. We conclude by discussing how combining existing iAI techniques with novel approaches could allow AI developers to better explain how their oculomics models work and reassure clinicians that the results issued are reliable.

Use of artificial intelligence with retinal imaging in screening for diabetes-associated complications: systematic review

Background

Artificial Intelligence (AI) has been used to automate detection of retinal diseases from retinal images with great success, in particular for screening for diabetic retinopathy, a major complication of diabetes. Since persons with diabetes routinely receive retinal imaging to evaluate their diabetic retinopathy status, AI-based retinal imaging may have potential to be used as an opportunistic comprehensive screening for multiple systemic micro- and macro-vascular complications of diabetes.

Methods

We conducted a qualitative systematic review on published literature using AI on retina images to detect systemic diabetes complications. We searched three main databases: PubMed, Google Scholar, and Web of Science (January 1, 2000, to October 1, 2024). Research that used AI to evaluate the associations between retinal images and diabetes-associated complications, or research involving diabetes patients with retinal imaging and AI systems were included. Our primary focus was on articles related to AI, retinal images, and diabetes-associated complications. We evaluated each study for the robustness of the studies by development of the AI algorithm, size and quality of the training dataset, internal validation and external testing, and the performance. Quality assessments were employed to ensure the inclusion of high-quality studies, and data extraction was conducted systematically to gather pertinent information for analysis. This study has been registered on PROSPERO under the registration ID CRD42023493512.

Findings

From a total of 337 abstracts, 38 studies were included. These studies covered a range of topics related to prediction of diabetes from pre-diabetes or non-diabeticindividuals (n = 4), diabetes related systemic risk factors (n = 10), detection of microvascular complications (n = 8) and detection of macrovascular complications (n = 17). Most studies (n = 32) utilized color fundus photographs (CFP) as retinal image modality, while others employed optical coherence tomography (OCT) (n = 6). The performance of the AI systems varied, with an AUC ranging from 0.676 to 0.971 in prediction or identification of different complications. Study designs included cross-sectional and cohort studies with sample sizes ranging from 100 to over 100,000 participants. Risk of bias was evaluated by using the Newcastle-Ottawa Scale and AXIS, with most studies scoring as low to moderate risk.

Interpretation

Our review highlights the potential for the use of AI algorithms applied to retina images, particularly CFP, to screen, predict, or diagnose the various microvascular and macrovascular complications of diabetes. However, we identified few studies with longitudinal data and a paucity of randomized control trials, reflecting a gap between the development of AI algorithms and real-world implementation and translational studies.

Funding

Dr. Gavin Siew Wei TAN is supported by: 1. DYNAMO: Diabetes studY on Nephropathy And other Microvascular cOmplications II supported by National Medical Research Council (MOH-001327-03): data collection, analysis, trial design 2. Prognositc significance of novel multimodal imaging markers for diabetic retinopathy: towards improving the staging for diabetic retinopathy supported by NMRC Clinician Scientist Award (CSA)-Investigator (INV) (MOH-001047-00).

Artificial intelligence in global health: An unfair future for health in Sub-Saharan Africa?

Artificial intelligence (AI) holds transformative potential for global health, particularly in underdeveloped regions like Africa. However, the integration of AI into healthcare systems raises significant concerns regarding equity and fairness. This debate paper explores the challenges and risks associated with implementing AI in healthcare in Africa, focusing on the lack of infrastructure, data quality issues, and inadequate governance frameworks. It also explores the geopolitical and economic dynamics that exacerbate these disparities, including the impact of global competition and weakened international institutions. While highlighting the risks, the paper acknowledges the potential benefits of AI, including improved healthcare access, standardization of care, and enhanced health communication. To ensure equitable outcomes, it advocates for targeted policy measures, including infrastructure investment, capacity building, regulatory frameworks, and international collaboration. This comprehensive approach is essential to mitigate risks, harness the benefits of AI, and promote social justice in global health.

ASSESSMENT OF ARTIFICIAL INTELLIGENCE SOFTWARE FOR AUTOMATIC SCREENING OF DIABETIC RETINOPATHY BASED ON FUNDUS PHOTOGRAPHS IN MELANODERM SUBJECTS

PURPOSE

To assess the Gaiha Prio Retino +™ Artificial Intelligence (AI) software for detecting diabetic retinopathy (DR).

METHODS

This prospective study was conducted from March 1, 2021, to September 30, 2022, in the Ophthalmology Department of the Abass NDAO Hospital (Dakar, Senegal). The clinical classification of DR was based on American Academy of Ophthalmology. The clinical results were compared with those obtained from the automated reading of retinophotos taken using Gaiha Prio Retino +™, a software designed to detect DR.

RESULTS

The study covered 305 eyes. Referable DR was observed in 104 eyes by the ophthalmologist and in 96 eyes by AI, corresponding with a sensitivity of 92.31%, a specificity of 99%, and an area under the curve of 0.989. Vision-threatening DR was detected in 102 eyes by the ophthalmologist and in 94 eyes by AI, with a corresponding sensitivity of 92.16%, specificity of 99.01%, and an area under the curve of 0.975. Maculopathy was identified in 93 eyes by the ophthalmologist and in 89 eyes by AI, with a corresponding sensitivity of 95.7%, specificity of 97.17%, and an area under the curve of 0.988.

CONCLUSION

Considering these results, the authors may conclude that Gaiha Prio Retino +™ is an effective tool for screening referable DR.

Transforming Non-Digital, Clinical Workflows to Detect and Track Vision-Threatening Diabetic Retinopathy via a Digital Platform Integrating Artificial Intelligence: Implementation Research

INTRODUCTION

Screening diabetic retinopathy (DR) for timely management can reduce global blindness. Many existing DR screening programs worldwide are non-digital, standalone, and deployed with grading retinal photographs by trained personnel. To integrate the screening programs, with or without artificial intelligence (AI), into hospital information systems to improve their effectiveness, the non-digital workflow must be transformed into digital. We developed a cloud-based digital platform and implemented it in an existing DR screening program.

METHODS

We conducted the following processes in the platform for prospective DR screening at a community hospital: capturing patients' retinal photographs, uploading them for grading by AI or trained personnel on alternate weeks for 32 weeks, and referring vision-threatening DR to a referral center. At this center, the platform was applied for the assessment of potential missed referrals via remote over-reading by a retinal specialist and tracking referrals. Implementational outcomes, such as detecting positive cases, agreement between AI and over-reading, and referral adherence were assessed.

RESULTS

Of 645 patients screened by AI, 201 (31.2%) were referrals, 129 (64.2%) of which were true positives agreeable by over-reading; 115 of these true positives (89.1%) had referral adherence. False negatives judged by over-reading were 1.1% (5/444). Of 730 patients in manual screening, 175 (24.0%) were potential referrals, 11 (6.3%) of which were referred at the point-of-screening; eight of these (72.7%) adhered to referral. The remaining 164 cases were appointed for later examination by a visiting general ophthalmologist; 11 of these 116 examined (9.5%) were referred for non-DR-related eye conditions with 81.8% (9/11) referral adherence. No system failure or interruption was found.

CONCLUSIONS

The digital platform can be practically integrated into the existing non-digital DR screening programs to implement AI and monitor previously unknown but important indicators, such as referral adherence, to improve the effectiveness of the programs.

TRIAL REGISTRATION

ClinicalTrials.gov. (registration number: NCT05166122).

Color fundus photograph-based diabetic retinopathy grading via label relaxed collaborative learning on deep features and radiomics features

Introduction

Diabetic retinopathy (DR) has long been recognized as a common complication of diabetes, making accurate automated grading of its severity essential. Color fundus photographs play a crucial role in the grading of DR. With the advancement of artificial intelligence technologies, numerous researchers have conducted studies on DR grading based on deep features and radiomic features extracted from color fundus photographs.

Method

We combine deep features and radiomic features to design a feature fusion algorithm. First, we utilize convolutional neural networks to extract deep features from color fundus photographs and employ radiomic methodologies to extract radiomic features. Subsequently, we design a label relaxation-based collaborative learning algorithm for feature fusion.

Results

We validate the effectiveness of the proposed method on two fundus image datasets: the DR1 Dataset and the MESSIDOR Dataset. The proposed method achieved 96.86 of AUC on DR1 and 96.34 of AUC on MESSIDOR, which are better than state-of-the-art methods. Also, the divergence between the training AUC and testing AUC increases substantially after the removal of manifold regularization.

Conclusion

Label relaxation can enhance the distinguishability of training samples in the label space, thereby improving the model's classification accuracy. Additionally, graph constraints based on manifold learning methods can mitigate overfitting caused by label relaxation.

Machine learning derived retinal pigment score from ophthalmic imaging shows ethnicity is not biology

Few metrics exist to describe phenotypic diversity within ophthalmic imaging datasets, with researchers often using ethnicity as a surrogate marker for biological variability. We derived a continuous, measured metric, the retinal pigment score (RPS), that quantifies the degree of pigmentation from a colour fundus photograph of the eye. RPS was validated using two large epidemiological studies with demographic and genetic data (UK Biobank and EPIC-Norfolk Study) and reproduced in a Tanzanian, an Australian, and a Chinese dataset. A genome-wide association study (GWAS) of RPS from UK Biobank identified 20 loci with known associations with skin, iris and hair pigmentation, of which eight were replicated in the EPIC-Norfolk cohort. There was a strong association between RPS and ethnicity, however, there was substantial overlap between each ethnicity and the respective distributions of RPS scores. RPS decouples traditional demographic variables from clinical imaging characteristics. RPS may serve as a useful metric to quantify the diversity of the training, validation, and testing datasets used in the development of AI algorithms to ensure adequate inclusion and explainability of the model performance, critical in evaluating all currently deployed AI models. The code to derive RPS is publicly available at: https://github.com/uw-biomedical-ml/retinal-pigmentation-score .

A Foundation Language-Image Model of the Retina (FLAIR): encoding expert knowledge in text supervision

Foundation vision-language models are currently transforming computer vision, and are on the rise in medical imaging fueled by their very promising generalization capabilities. However, the initial attempts to transfer this new paradigm to medical imaging have shown less impressive performances than those observed in other domains, due to the significant domain shift and the complex, expert domain knowledge inherent to medical-imaging tasks. Motivated by the need for domain-expert foundation models, we present FLAIR, a pre-trained vision-language model for universal retinal fundus image understanding. To this end, we compiled 38 open-access, mostly categorical fundus imaging datasets from various sources, with up to 101 different target conditions and 288,307 images. We integrate the expert's domain knowledge in the form of descriptive textual prompts, during both pre-training and zero-shot inference, enhancing the less-informative categorical supervision of the data. Such a textual expert's knowledge, which we compiled from the relevant clinical literature and community standards, describes the fine-grained features of the pathologies as well as the hierarchies and dependencies between them. We report comprehensive evaluations, which illustrate the benefit of integrating expert knowledge and the strong generalization capabilities of FLAIR under difficult scenarios with domain shifts or unseen categories. When adapted with a lightweight linear probe, FLAIR outperforms fully-trained, dataset-focused models, more so in the few-shot regimes. Interestingly, FLAIR outperforms by a wide margin larger-scale generalist image-language models and retina domain-specific self-supervised networks, which emphasizes the potential of embedding experts' domain knowledge and the limitations of generalist models in medical imaging. The pre-trained model is available at: https://github.com/jusiro/FLAIR.

Narrative review of comprehensive management strategies for diabetic retinopathy: interdisciplinary approaches and future perspectives

This review examines the epidemiological trends, pathophysiologic mechanisms, and current and future therapeutic strategies for diabetic retinopathy (DR), focusing on innovative management countermeasures in the face of this global public health challenge. As the number of patients with diabetes continues to increase, DR, as one of its major complications, poses a significant threat to global visual health. This review not only summarises the latest advances in personalised treatment and emerging therapeutic modalities (such as anti-vascular endothelial growth factor therapy, laser treatment, surgical procedures and cutting-edge gene and stem cell therapies) but also emphasises the revolutionary potential of telemedicine technologies and digital health platforms to improve DR screening and adherence among people with diabetes. We show how these technological innovations, especially in resource-limited settings, can achieve early diagnosis and effective treatment, thereby significantly reducing the public health burden of DR. In addition, this article highlights the critical role of interdisciplinary teamwork in optimising the comprehensive management of DR, involving close collaboration among physicians, researchers, patient education specialists and policy-makers, as well as the importance of implementing these innovative solutions through societal engagement and policy support. By highlighting these innovative strategies and their specific impact on improving public health practices, this review offers new perspectives and strategies for the future management of DR, with the goal of promoting the prevention, diagnosis and treatment of DR worldwide, improving patient prognosis and enhancing quality of life.

A deep learning-based ADRPPA algorithm for the prediction of diabetic retinopathy progression

As an alternative to assessments performed by human experts, artificial intelligence (AI) is currently being used for screening fundus images and monitoring diabetic retinopathy (DR). Although AI models can provide quasi-clinician diagnoses, they rarely offer new insights to assist clinicians in predicting disease prognosis and treatment response. Using longitudinal retinal imaging data, we developed and validated a predictive model for DR progression: AI-driven Diabetic Retinopathy Progression Prediction Algorithm (ADRPPA). In this retrospective study, we analyzed paired retinal fundus images of the same eye captured at ≥ 1-year intervals. The analysis was performed using the EyePACS dataset. By analyzing 12,768 images from 6384 eyes (2 images/eye, taken 733 ± 353 days apart), each annotated with DR severity grades, we trained the neural network ResNeXt to automatically determine DR severity. EyePACS data corresponding to 5108 (80%), 639 (10%), and 637 (10%) eyes were used for model training, validation, and testing, respectively. We further used an independent e-ophtha dataset comprising 148 images annotated with microaneurysms, 118 (75%) and 30 (25%) of which were used for training and validation, respectively. This dataset was used to train the neural network Mask Region-based Convolutional Neural Network (Mask-RCNN) for quantifying microaneurysms. The DR and microaneurysm scores from the first nonreferable DR (NRDR) image of each eye were used to predict progression to referable DR (RDR) in the second image. The area under the receiver operating characteristic curve values indicating our model's performance in diagnosing RDR were 0.963, 0.970, 0.968, and 0.971 for the trained ResNeXt models with input image resolutions of 256 × 256, 512 × 512, 768 × 768, and 1024 × 1024 pixels, respectively. In the validation of the Mask-RCNN model trained on the e-ophtha dataset resized to 1600 pixels in height, the recall, precision, and F1-score values for detecting individual microaneurysms were 0.786, 0.615, and 0.690, respectively. The best model combination for predicting NRDR-to-RDR progression included the 768-pixel ResNeXt and 1600-pixel Mask-RCNN models; this combination achieved recall, precision, and F1-scores of 0.338 (95% confidence interval [CI]: 0.228-0.451), 0.561 (95% CI: 0.405-0.714), and 0.422 (95% CI: 0.299-0.532), respectively. Thus, deep learning models can be trained on longitudinal retinal imaging data to predict NRDR-to-RDR progression. Furthermore, DR and microaneurysm scores generated from low- and high-resolution fundus images, respectively, can help identify patients at a high risk of NRDR, facilitating timely treatment.

Innovations in Diabetes Management for Pregnant Women: Artificial Intelligence and the Internet of Medical Things

Pregnancies impacted by diabetes face the compounded challenge of strict glycemic control with mounting insulin resistance as the pregnancy progresses. New technological advances, including artificial intelligence (AI) and the Internet of Medical Things (IoMT), are revolutionizing health care delivery by providing innovative solutions for diabetes care during pregnancy. Together, AI and the IoMT are a multibillion-dollar industry that integrates advanced medical devices and sensors into a connected network that enables continuous monitoring of glucose levels. AI-driven clinical decision support systems (CDSSs) can predict glucose trends and provide tailored evidence-based treatments with real-time adjustments as insulin resistance changes with placental growth. Additionally, mobile health (mHealth) applications facilitate patient education and self-management through real-time tracking of diet, physical activity, and glucose levels. Remote monitoring capabilities are particularly beneficial for pregnant persons with diabetes as they extend quality care to underserved populations and reduce the need for frequent in-person visits. This high-resolution monitoring allows physicians and patients access to an unprecedented wealth of data to make more informed decisions based on real-time data, reducing complications for both the mother and fetus. These technologies can potentially improve maternal and fetal outcomes by enabling timely, individualized interventions based on personalized health data. While AI and IoMT offer significant promise in enhancing diabetes care for improved maternal and fetal outcomes, their implementation must address challenges such as data security, cost-effectiveness, and preserving the essential patient-provider relationship. KEY POINTS: · The IoMT expands how patients interact with their health care.. · AI has widespread application in the care of pregnancies complicated by diabetes.. · A need for validation and black-box methodologies challenges the application of AI-based tools.. · As research in AI grows, considerations for data privacy and ethical dilemmas will be required..

Ensemble deep learning and EfficientNet for accurate diagnosis of diabetic retinopathy

Diabetic Retinopathy (DR) stands as a significant global cause of vision impairment, underscoring the critical importance of early detection in mitigating its impact. Addressing this challenge head-on, this study introduces an innovative deep learning framework tailored for DR diagnosis. The proposed framework utilizes the EfficientNetB0 architecture to classify diabetic retinopathy severity levels from retinal images. By harnessing advanced techniques in computer vision and machine learning, the proposed model aims to deliver precise and dependable DR diagnoses. Continuous testing and experimentation shows to the efficiency of the architecture, showcasing promising outcomes that could help in the transformation of both diagnosing and treatment of DR. This framework takes help from the EfficientNet Machine Learning algorithms and employing advanced CNN layering techniques. The dataset utilized in this study is titled 'Diagnosis of Diabetic Retinopathy' and is sourced from Kaggle. It consists of 35,108 retinal images, classified into five categories: No Diabetic Retinopathy (DR), Mild DR, Moderate DR, Severe DR, and Proliferative DR. Through rigorous testing, the framework yields impressive results, boasting an average accuracy of 86.53% and a loss rate of 0.5663. A comparison with alternative approaches underscores the effectiveness of EfficientNet in handling classification tasks for diabetic retinopathy, particularly highlighting its high accuracy and generalizability across DR severity levels. These findings highlight the framework's potential to significantly advance the field of DR diagnosis, given more advanced datasets and more training resources which leads it to be offering clinicians a powerful tool for early intervention and improved patient outcomes.

From theoretical models to practical deployment: A perspective and case study of opportunities and challenges in AI-driven cardiac auscultation research for low-income settings

This article includes a literature review and a case study of artificial intelligence (AI) heart murmur detection models to analyse the opportunities and challenges in deploying AI in cardiovascular healthcare in low- or medium-income countries (LMICs). This study has two parallel components: (1) The literature review assesses the capacity of AI to aid in addressing the observed disparity in healthcare between high- and low-income countries. Reasons for the limited deployment of machine learning models are discussed, as well as model generalisation. Moreover, the literature review discusses how emerging human-centred deployment research is a promising avenue for overcoming deployment barriers. (2) A predictive AI screening model is developed and tested in a case study on heart murmur detection in rural Brazil. Our binary Bayesian ResNet model leverages overlapping log mel spectrograms of patient heart sound recordings and integrates demographic data and signal features via XGBoost to optimise performance. This is followed by a discussion of the model's limitations, its robustness, and the obstacles preventing its practical application. The difficulty with which this model, and other state-of-the-art models, generalise to out-of-distribution data is also discussed. By integrating the results of the case study with those of the literature review, the NASSS framework was applied to evaluate the key challenges in deploying AI-supported heart murmur detection in low-income settings. The research accentuates the transformative potential of AI-enabled healthcare, particularly for affordable point-of-care screening systems in low-income settings. It also emphasises the necessity of effective implementation and integration strategies to guarantee the successful deployment of these technologies.

Implementation of deep learning artificial intelligence in vision-threatening disease screenings for an underserved community during COVID-19

INTRODUCTION

Age-related macular degeneration, diabetic retinopathy, and glaucoma are vision-threatening diseases that are leading causes of vision loss. Many studies have validated deep learning artificial intelligence for image-based diagnosis of vision-threatening diseases. Our study prospectively investigated deep learning artificial intelligence applications in student-run non-mydriatic screenings for an underserved, primarily Hispanic community during COVID-19.

METHODS

Five supervised student-run community screenings were held in West New York, New Jersey. Participants underwent non-mydriatic 45-degree retinal imaging by medical students. Images were uploaded to a cloud-based deep learning artificial intelligence for vision-threatening disease referral. An on-site tele-ophthalmology grader and remote clinical ophthalmologist graded images, with adjudication by a senior ophthalmologist to establish the gold standard diagnosis, which was used to assess the performance of deep learning artificial intelligence.

RESULTS

A total of 385 eyes from 195 screening participants were included (mean age 52.43  ±  14.5 years, 40.0% female). A total of 48 participants were referred for at least one vision-threatening disease. Deep learning artificial intelligence marked 150/385 (38.9%) eyes as ungradable, compared to 10/385 (2.6%) ungradable as per the human gold standard (p < 0.001). Deep learning artificial intelligence had 63.2% sensitivity, 94.5% specificity, 32.0% positive predictive value, and 98.4% negative predictive value in vision-threatening disease referrals. Deep learning artificial intelligence successfully referred all 4 eyes with multiple vision-threatening diseases. Deep learning artificial intelligence graded images (35.6  ±  13.3 s) faster than the tele-ophthalmology grader (129  ±  41.0) and clinical ophthalmologist (68  ±  21.9, p < 0.001).

DISCUSSION

Deep learning artificial intelligence can increase the efficiency and accessibility of vision-threatening disease screenings, particularly in underserved communities. Deep learning artificial intelligence should be adaptable to different environments. Consideration should be given to how deep learning artificial intelligence can best be utilized in a real-world application, whether in computer-aided or autonomous diagnosis.

A foundation for evaluating the surgical artificial intelligence literature

With increasing growth in applications of artificial intelligence (AI) in surgery, it has become essential for surgeons to gain a foundation of knowledge to critically appraise the scientific literature, commercial claims regarding products, and regulatory and legal frameworks that govern the development and use of AI. This guide offers surgeons a framework with which to evaluate manuscripts that incorporate the use of AI. It provides a glossary of common terms, an overview of prerequisite knowledge to maximize understanding of methodology, and recommendations on how to carefully consider each element of a manuscript to assess the quality of the data on which an algorithm was trained, the appropriateness of the methodological approach, the potential for reproducibility of the experiment, and the applicability to surgical practice, including considerations on generalizability and scalability.

Imaging the eye as a window to brain health: frontier approaches and future directions

Recent years have seen significant advances in diagnostic testing of central nervous system (CNS) function and disease. However, there remain challenges in developing a comprehensive suite of non- or minimally invasive assays of neural health and disease progression. Due to the direct connection with the CNS, structural changes in the neural retina, retinal vasculature and morphological changes in retinal immune cells can occur in parallel with disease conditions in the brain. The retina can also, uniquely, be assessed directly and non-invasively. For these reasons, the retina may prove to be an important "window" for revealing and understanding brain disease. In this review, we discuss the gross anatomy of the eye, focusing on the sensory and non-sensory cells of the retina, especially microglia, that lend themselves to diagnosing brain disease by imaging the retina. We include a history of ocular imaging to describe the different imaging approaches undertaken in the past and outline current and emerging technologies including retinal autofluorescence imaging, Raman spectroscopy, and artificial intelligence image analysis. These new technologies show promising potential for retinal imaging to be used as a tool for the diagnosis of brain disorders such as Alzheimer's disease and others and the assessment of treatment success.

Health Data Sciences and Cardiovascular Disease in Africa: Needs and the Way Forward

PURPOSE OF REVIEW

The rising burden of cardiovascular disease (CVD) in Africa is of great concern. Health data sciences is a rapidly developing field which has the potential to improve health outcomes, especially in low-middle income countries with burdened healthcare systems. We aim to explore the current CVD landscape in Africa, highlighting the importance of health data sciences in the region and identifying potential opportunities for application and growth by leveraging health data sciences to improve CVD outcomes.

RECENT FINDINGS

While there have been a number of initiatives aimed at developing health data sciences in Africa over the recent decades, the progress and growth are still in their early stages. Its maximum potential can be leveraged through adequate funding, advanced training programs, focused resource allocation, encouraging bidirectional international partnerships, instituting best ethical practices, and prioritizing data science health research in the region. The findings of this review explore the current landscape of CVD and highlight the potential benefits and utility of health data sciences to address CVD challenges in Africa. By understanding and overcoming the barriers associated with health data sciences training, research, and application in the region, focused initiatives can be developed to promote research and development. These efforts will allow policymakers to form informed, evidence-based frameworks for the prevention and management of CVDs, and ultimately result in improved CVD outcomes in the region.

The Ubuntu Way: Ensuring Ethical AI Integration in Health Research

The integration of artificial intelligence (AI) in health research has grown rapidly, particularly in African nations, which have also been developing data protection laws and AI strategies. However, the ethical frameworks governing AI use in health research are often based on Western philosophies, focusing on individualism, and may not fully address the unique challenges and cultural contexts of African communities. This paper advocates for the incorporation of African philosophies, specifically Ubuntu, into AI health research ethics frameworks to better align with African values and contexts. This study explores the concept of Ubuntu, a philosophy that emphasises communalism, interconnectedness, and collective well-being, and its application to AI health research ethics. By analysing existing global AI ethics frameworks and contrasting them with the Ubuntu philosophy, a new ethics framework is proposed that integrates these perspectives. The framework is designed to address ethical challenges at individual, community, national, and environmental levels, with a particular focus on the African context. The proposed framework highlights four key principles derived from Ubuntu: communalism and openness, harmony and support, research prioritisation and community empowerment, and community-oriented decision-making. These principles are aligned with global ethical standards such as justice, beneficence, transparency, and accountability but are adapted to reflect the communal and relational values inherent in Ubuntu. The framework aims to ensure that AI-driven health research benefits communities equitably, respects local contexts and promotes long-term sustainability. Integrating Ubuntu into AI health research ethics can address the limitations of current frameworks that emphasise individualism. This approach not only aligns with African values but also offers a model that could be applied more broadly to enhance the ethical governance of AI in health research worldwide. By prioritising communal well-being, inclusivity, and environmental stewardship, the proposed framework has the potential to foster more responsible and contextually relevant AI health research practices in Africa.

The application of artificial intelligence in diabetic retinopathy: progress and prospects

In recent years, artificial intelligence (AI), especially deep learning models, has increasingly been integrated into diagnosing and treating diabetic retinopathy (DR). From delving into the singular realm of ocular fundus photography to the gradual development of proteomics and other molecular approaches, from machine learning (ML) to deep learning (DL), the journey has seen a transition from a binary diagnosis of "presence or absence" to the capability of discerning the progression and severity of DR based on images from various stages of the disease course. Since the FDA approval of IDx-DR in 2018, a plethora of AI models has mushroomed, gradually gaining recognition through a myriad of clinical trials and validations. AI has greatly improved early DR detection, and we're nearing the use of AI in telemedicine to tackle medical resource shortages and health inequities in various areas. This comprehensive review meticulously analyzes the literature and clinical trials of recent years, highlighting key AI models for DR diagnosis and treatment, including their theoretical bases, features, applicability, and addressing current challenges like bias, transparency, and ethics. It also presents a prospective outlook on the future development in this domain.

Trends and hotspots in the field of diabetic retinopathy imaging research from 2000-2023

Background

Diabetic retinopathy (DR) poses a major threat to diabetic patients' vision and is a critical public health issue. Imaging applications for DR have grown since the 21st century, aiding diagnosis, grading, and screening. This study uses bibliometric analysis to assess the field's advancements and key areas of interest.

Methods

This study performed a bibliometric analysis of DR imaging articles collected from the Web of Science Core Collection database between January 1st, 2000, and December 31st, 2023. The literature information was then analyzed through CiteSpace.

Results

The United States and China led in the number of publications, with 719 and 609, respectively. The University of London topped the institution list with 139 papers. Tien Yin Wong was the most prolific researcher. Invest. Ophthalmol. Vis. Sci. published the most articles (105). Notable burst keywords were "deep learning," "artificial intelligence," et al.

Conclusion

The United States is at the forefront of DR research, with the University of London as the top institution and Invest. Ophthalmol. Vis. Sci. as the most published journal. Tien Yin Wong is the most influential researcher. Hotspots like "deep learning," and "artificial intelligence," have seen a significant rise, indicating artificial intelligence's growing role in DR imaging.

Discriminative, generative artificial intelligence, and foundation models in retina imaging

Recent advances of artificial intelligence (AI) in retinal imaging found its application in two major categories: discriminative and generative AI. For discriminative tasks, conventional convolutional neural networks (CNNs) are still major AI techniques. Vision transformers (ViT), inspired by the transformer architecture in natural language processing, has emerged as useful techniques for discriminating retinal images. ViT can attain excellent results when pretrained at sufficient scale and transferred to specific tasks with fewer images, compared to conventional CNN. Many studies found better performance of ViT, compared to CNN, for common tasks such as diabetic retinopathy screening on color fundus photographs (CFP) and segmentation of retinal fluid on optical coherence tomography (OCT) images. Generative Adversarial Network (GAN) is the main AI technique in generative AI in retinal imaging. Novel images generated by GAN can be applied for training AI models in imbalanced or inadequate datasets. Foundation models are also recent advances in retinal imaging. They are pretrained with huge datasets, such as millions of CFP and OCT images and fine-tuned for downstream tasks with much smaller datasets. A foundation model, RETFound, which was self-supervised and found to discriminate many eye and systemic diseases better than supervised models. Large language models are foundation models that may be applied for text-related tasks, like reports of retinal angiography. Whereas AI technology moves forward fast, real-world use of AI models moves slowly, making the gap between development and deployment even wider. Strong evidence showing AI models can prevent visual loss may be required to close this gap.

Current research and future strategies for the management of vision-threatening diabetic retinopathy

Diabetic retinopathy (DR) is a major ocular complication of diabetes and the leading cause of blindness and visual impairment, particularly among adults of working-age adults. Although the medical and economic burden of DR is significant and its global prevalence is expected to increase, particularly in low- and middle-income countries, a large portion of vision loss caused by DR remains preventable through early detection and timely intervention. This perspective reviewed the latest developments in research and innovation in three areas, first novel biomarkers (including advanced imaging modalities, serum biomarkers, and artificial intelligence technology) to predict the incidence and progression of DR, second, screening and early detection of referable DR and vision-threatening DR (VTDR), and finally, novel therapeutic strategies for VTDR, including diabetic macular oedema (DME), with the goal of reducing diabetic blindness.

Advancing healthcare with artificial intelligence: diagnostic accuracy of machine learning algorithm in diagnosis of diabetic retinopathy in the Brazilian population

BACKGROUND

In healthcare systems in general, access to diabetic retinopathy (DR) screening is limited. Artificial intelligence has the potential to increase care delivery. Therefore, we trained and evaluated the diagnostic accuracy of a machine learning algorithm for automated detection of DR.

METHODS

We included color fundus photographs from individuals from 4 databases (primary and specialized care settings), excluding uninterpretable images. The datasets consist of images from Brazilian patients, which differs from previous work. This modification allows for a more tailored application of the model to Brazilian patients, ensuring that the nuances and characteristics of this specific population are adequately captured. The sample was fractionated in training (70%) and testing (30%) samples. A convolutional neural network was trained for image classification. The reference test was the combined decision from three ophthalmologists. The sensitivity, specificity, and area under the ROC curve of the algorithm for detecting referable DR (moderate non-proliferative DR; severe non-proliferative DR; proliferative DR and/or clinically significant macular edema) were estimated.

RESULTS

A total of 15,816 images (4590 patients) were included. The overall prevalence of any degree of DR was 26.5%. Compared with human evaluators (manual method of diagnosing DR performed by an ophthalmologist), the deep learning algorithm achieved an area under the ROC curve of 0.98 (95% CI 0.97-0.98), with a specificity of 94.6% (95% CI 93.8-95.3) and a sensitivity of 93.5% (95% CI 92.2-94.9) at the point of greatest efficiency to detect referable DR.

CONCLUSIONS

A large database showed that this deep learning algorithm was accurate in detecting referable DR. This finding aids to universal healthcare systems like Brazil, optimizing screening processes and can serve as a tool for improving DR screening, making it more agile and expanding care access.

Evaluation of an AI algorithm trained on an ethnically diverse dataset to screen a previously unseen population for diabetic retinopathy

PURPOSE

This study aimed to determine the generalizability of an artificial intelligence (AI) algorithm trained on an ethnically diverse dataset to screen for referable diabetic retinopathy (RDR) in the Armenian population unseen during AI development.

METHODS

This study comprised 550 patients with diabetes mellitus visiting the polyclinics of Armenia over 10 months requiring diabetic retinopathy (DR) screening. The Medios AI-DR algorithm was developed using a robust, diverse, ethnically balanced dataset with no inherent bias and deployed offline on a smartphone-based fundus camera. The algorithm here analyzed the retinal images captured using the target device for the presence of RDR (i.e., moderate non-proliferative diabetic retinopathy (NPDR) and/or clinically significant diabetic macular edema (CSDME) or more severe disease) and sight-threatening DR (STDR, i.e., severe NPDR and/or CSDME or more severe disease). The results compared the AI output to a consensus or majority image grading of three expert graders according to the International Clinical Diabetic Retinopathy severity scale.

RESULTS

On 478 subjects included in the analysis, the algorithm achieved a high classification sensitivity of 95.30% (95% CI: 91.9%-98.7%) and a specificity of 83.89% (95% CI: 79.9%-87.9%) for the detection of RDR. The sensitivity for STDR detection was 100%.

CONCLUSION

The study proved that Medios AI-DR algorithm yields good accuracy in screening for RDR in the Armenian population. In our literature search, this is the only smartphone-based, offline AI model validated in different populations.

Artificial intelligence for diabetes care: current and future prospects

Artificial intelligence (AI) use in diabetes care is increasingly being explored to personalise care for people with diabetes and adapt treatments for complex presentations. However, the rapid advancement of AI also introduces challenges such as potential biases, ethical considerations, and implementation challenges in ensuring that its deployment is equitable. Ensuring inclusive and ethical developments of AI technology can empower both health-care providers and people with diabetes in managing the condition. In this Review, we explore and summarise the current and future prospects of AI across the diabetes care continuum, from enhancing screening and diagnosis to optimising treatment and predicting and managing complications.

Artificial Intelligence (AI)-Enhanced Detection of Diabetic Retinopathy From Fundus Images: The Current Landscape and Future Directions

Diabetic retinopathy (DR) remains a leading cause of vision loss worldwide, with early detection critical for preventing irreversible damage. This review explores the current landscape and future directions of artificial intelligence (AI)-enhanced detection of DR from fundus images. Recent advances in deep learning and computer vision have enabled AI systems to analyze retinal images with expert-level accuracy, potentially transforming DR screening. Key developments include convolutional neural networks achieving high sensitivity and specificity in detecting referable DR, multi-task learning approaches that can simultaneously detect and grade DR severity, and lightweight models enabling deployment on mobile devices. While these AI systems show promise in improving the efficiency and accessibility of DR screening, several challenges remain. These include ensuring generalizability across diverse populations, standardizing image acquisition and quality, addressing the "black box" nature of complex models, and integrating AI seamlessly into clinical workflows. Future directions in the field encompass explainable AI to enhance transparency, federated learning to leverage decentralized datasets, and the integration of AI with electronic health records and other diagnostic modalities. There is also growing potential for AI to contribute to personalized treatment planning and predictive analytics for disease progression. As the technology continues to evolve, maintaining a focus on rigorous clinical validation, ethical considerations, and real-world implementation will be crucial for realizing the full potential of AI-enhanced DR detection in improving global eye health outcomes.

A systematic review of economic evaluation of artificial intelligence-based screening for eye diseases: From possibility to reality

Artificial Intelligence (AI) has become a focus of research in the rapidly evolving field of ophthalmology. Nevertheless, there is a lack of systematic studies on the health economics of AI in this field. We examine studies from the PubMed, Google Scholar, and Web of Science databases that employed quantitative analysis, retrieved up to July 2023. Most of the studies indicate that AI leads to cost savings and improved efficiency in ophthalmology. On the other hand, some studies suggest that using AI in healthcare may raise costs for patients, especially when taking into account factors such as labor costs, infrastructure, and patient adherence. Future research should cover a wider range of ophthalmic diseases beyond common eye conditions. Moreover, conducting extensive health economic research, designed to collect data relevant to its own context, is imperative.

Diagnostic Accuracy of Artificial Intelligence-Based Automated Diabetic Retinopathy Screening in Real-World Settings: A Systematic Review and Meta-Analysis

PURPOSE

To evaluate the diagnostic accuracy of artificial intelligence (AI)-based automated diabetic retinopathy (DR) screening in real-world settings.

DESIGN

Systematic review and meta-analysis METHODS: We conducted a systematic review of relevant literature from January 2012 to August 2022 using databases including PubMed, Scopus and Web of Science. The quality of studies was evaluated using Quality Assessment for Diagnostic Accuracy Studies 2 (QUADAS-2) checklist. We calculated pooled accuracy, sensitivity, specificity, and diagnostic odds ratio (DOR) as summary measures. The study protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO - CRD42022367034).

RESULTS

We included 34 studies which utilized AI algorithms for diagnosing DR based on real-world fundus images. Quality assessment of these studies indicated a low risk of bias and low applicability concern. Among gradable images, the overall pooled accuracy, sensitivity, specificity, and DOR were 81%, 94% (95% CI: 92.0-96.0), 89% (95% CI: 85.0-92.0) and 128 (95% CI: 80-204) respectively. Sub-group analysis showed that, when acceptable quality imaging could be obtained, non-mydriatic fundus images had a better DOR of 143 (95% CI: 82-251) and studies using 2 field images had a better DOR of 161 (95% CI 74-347). Our meta-regression analysis revealed a statistically significant association between DOR and variables such as the income status, and the type of fundus camera.

CONCLUSION

Our findings indicate that AI algorithms have acceptable performance in screening for DR using fundus images compared to human graders. Implementing a fundus camera with AI-based software has the potential to assist ophthalmologists in reducing their workload and improving the accuracy of DR diagnosis.

Construction of Risk Prediction Model of Type 2 Diabetic Kidney Disease Based on Deep Learning

BACKGRUOUND

This study aimed to develop a diabetic kidney disease (DKD) prediction model using long short term memory (LSTM) neural network and evaluate its performance using accuracy, precision, recall, and area under the curve (AUC) of the receiver operating characteristic (ROC) curve.

METHODS

The study identified DKD risk factors through literature review and physician focus group, and collected 7 years of data from 6,040 type 2 diabetes mellitus patients based on the risk factors. Pytorch was used to build the LSTM neural network, with 70% of the data used for training and the other 30% for testing. Three models were established to examine the impact of glycosylated hemoglobin (HbA1c), systolic blood pressure (SBP), and pulse pressure (PP) variabilities on the model's performance.

RESULTS

The developed model achieved an accuracy of 83% and an AUC of 0.83. When the risk factor of HbA1c variability, SBP variability, or PP variability was removed one by one, the accuracy of each model was significantly lower than that of the optimal model, with an accuracy of 78% (P<0.001), 79% (P<0.001), and 81% (P<0.001), respectively. The AUC of ROC was also significantly lower for each model, with values of 0.72 (P<0.001), 0.75 (P<0.001), and 0.77 (P<0.05).

CONCLUSION

The developed DKD risk predictive model using LSTM neural networks demonstrated high accuracy and AUC value. When HbA1c, SBP, and PP variabilities were added to the model as featured characteristics, the model's performance was greatly improved.

Transparency in Artificial Intelligence Reporting in Ophthalmology-A Scoping Review

Topic

This scoping review summarizes artificial intelligence (AI) reporting in ophthalmology literature in respect to model development and validation. We characterize the state of transparency in reporting of studies prospectively validating models for disease classification.

Clinical Relevance

Understanding what elements authors currently describe regarding their AI models may aid in the future standardization of reporting. This review highlights the need for transparency to facilitate the critical appraisal of models prior to clinical implementation, to minimize bias and inappropriate use. Transparent reporting can improve effective and equitable use in clinical settings.

Methods

Eligible articles (as of January 2022) from PubMed, Embase, Web of Science, and CINAHL were independently screened by 2 reviewers. All observational and clinical trial studies evaluating the performance of an AI model for disease classification of ophthalmic conditions were included. Studies were evaluated for reporting of parameters derived from reporting guidelines (CONSORT-AI, MI-CLAIM) and our previously published editorial on model cards. The reporting of these factors, which included basic model and dataset details (source, demographics), and prospective validation outcomes, were summarized.

Results

Thirty-seven prospective validation studies were included in the scoping review. Eleven additional associated training and/or retrospective validation studies were included if this information could not be determined from the primary articles. These 37 studies validated 27 unique AI models; multiple studies evaluated the same algorithms (EyeArt, IDx-DR, and Medios AI). Details of model development were variably reported; 18 of 27 models described training dataset annotation and 10 of 27 studies reported training data distribution. Demographic information of training data was rarely reported; 7 of the 27 unique models reported age and gender and only 2 reported race and/or ethnicity. At the level of prospective clinical validation, age and gender of populations was more consistently reported (29 and 28 of 37 studies, respectively), but only 9 studies reported race and/or ethnicity data. Scope of use was difficult to discern for the majority of models. Fifteen studies did not state or imply primary users.

Conclusion

Our scoping review demonstrates variable reporting of information related to both model development and validation. The intention of our study was not to assess the quality of the factors we examined, but to characterize what information is, and is not, regularly reported. Our results suggest the need for greater transparency in the reporting of information necessary to determine the appropriateness and fairness of these tools prior to clinical use.

Financial Disclosures

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Diabetes management in the era of artificial intelligence

Artificial intelligence is growing quickly, and its application in the global diabetes pandemic has the potential to completely change the way this chronic illness is identified and treated. Machine learning methods have been used to construct algorithms supporting predictive models for the risk of getting diabetes or its complications. Social media and Internet forums also increase patient participation in diabetes care. Diabetes resource usage optimisation has benefited from technological improvements. As a lifestyle therapy intervention, digital therapies have made a name for themselves in the treatment of diabetes. Artificial intelligence will cause a paradigm shift in diabetes care, moving away from current methods and toward the creation of focused, data-driven precision treatment.

Advancing healthcare: the role and impact of AI and foundation models

BACKGROUND

The integration of artificial intelligence (AI) into the healthcare domain is a monumental shift with profound implications for diagnostics, medical interventions, and the overall structure of healthcare systems.

PURPOSE

This study explores the transformative journey of foundation AI models in healthcare, shedding light on the challenges, ethical considerations, and vast potential they hold for improving patient outcome and system efficiency. Notably, in this investigation we observe a relatively slow adoption of AI within the public sector of healthcare. The evolution of AI in healthcare is un-paralleled, especially its prowess in revolutionizing diagnostic processes.

RESULTS

This research showcases how these foundational models can unravel hidden patterns within complex medical datasets. The impact of AI reverberates through medical interventions, encompassing pathology, imaging, genomics, and personalized healthcare, positioning AI as a cornerstone in the quest for precision medicine. The paper delves into the applications of generative AI models in critical facets of healthcare, including decision support, medical imaging, and the prediction of protein structures. The study meticulously evaluates various AI models, such as transfer learning, RNN, autoencoders, and their roles in the healthcare landscape. A pioneering concept introduced in this exploration is that of General Medical AI (GMAI), advocating for the development of reusable and flexible AI models.

CONCLUSION

The review article discusses how AI can revolutionize healthcare by stressing the significance of transparency, fairness and accountability, in AI applications regarding patient data privacy and biases. By tackling these issues and suggesting a governance structure the article adds to the conversation about AI integration in healthcare environments.

Challenges and Potential of Artificial Intelligence in Neuroradiology

PURPOSE

Artificial intelligence (AI) has emerged as a transformative force in medical research and is garnering increased attention in the public consciousness. This represents a critical time period in which medical researchers, healthcare providers, insurers, regulatory agencies, and patients are all developing and shaping their beliefs and policies regarding the use of AI in the healthcare sector. The successful deployment of AI will require support from all these groups. This commentary proposes that widespread support for medical AI must be driven by clear and transparent scientific reporting, beginning at the earliest stages of scientific research.

METHODS

A review of relevant guidelines and literature describing how scientific reporting plays a central role at key stages in the life cycle of an AI software product was conducted. To contextualize this principle within a specific medical domain, we discuss the current state of predictive tissue outcome modeling in acute ischemic stroke and the unique challenges presented therein.

RESULTS AND CONCLUSION

Translating AI methods from the research to the clinical domain is complicated by challenges related to model design and validation studies, medical product regulations, and healthcare providers' reservations regarding AI's efficacy and affordability. However, each of these limitations is also an opportunity for high-impact research that will help to accelerate the clinical adoption of state-of-the-art medical AI. In all cases, establishing and adhering to appropriate reporting standards is an important responsibility that is shared by all of the parties involved in the life cycle of a prospective AI software product.

Feasibility and acceptance of artificial intelligence-based diabetic retinopathy screening in Rwanda

BACKGROUND

Evidence on the practical application of artificial intelligence (AI)-based diabetic retinopathy (DR) screening is needed.

METHODS

Consented participants were screened for DR using retinal imaging with AI interpretation from March 2021 to June 2021 at four diabetes clinics in Rwanda. Additionally, images were graded by a UK National Health System-certified retinal image grader. DR grades based on the International Classification of Diabetic Retinopathy with a grade of 2.0 or higher were considered referable. The AI system was designed to detect optic nerve and macular anomalies outside of DR. A vertical cup to disc ratio of 0.7 and higher and/or macular anomalies recognised at a cut-off of 60% and higher were also considered referable by AI.

RESULTS

Among 827 participants (59.6% women (n=493)) screened by AI, 33.2% (n=275) were referred for follow-up. Satisfaction with AI screening was high (99.5%, n=823), and 63.7% of participants (n=527) preferred AI over human grading. Compared with human grading, the sensitivity of the AI for referable DR was 92% (95% CI 0.863%, 0.968%), with a specificity of 85% (95% CI 0.751%, 0.882%). Of the participants referred by AI: 88 (32.0%) were for DR only, 109 (39.6%) for DR and an anomaly, 65 (23.6%) for an anomaly only and 13 (4.73%) for other reasons. Adherence to referrals was highest for those referred for DR at 53.4%.

CONCLUSION

DR screening using AI led to accurate referrals from diabetes clinics in Rwanda and high rates of participant satisfaction, suggesting AI screening for DR is practical and acceptable.

Deep Learning Approaches for Detecting of Nascent Geographic Atrophy in Age-Related Macular Degeneration

Purpose

Nascent geographic atrophy (nGA) refers to specific features seen on OCT B-scans, which are strongly associated with the future development of geographic atrophy (GA). This study sought to develop a deep learning model to screen OCT B-scans for nGA that warrant further manual review (an artificial intelligence [AI]-assisted approach), and to determine the extent of reduction in OCT B-scan load requiring manual review while maintaining near-perfect nGA detection performance.

Design

Development and evaluation of a deep learning model.

Participants

One thousand eight hundred and eighty four OCT volume scans (49 B-scans per volume) without neovascular age-related macular degeneration from 280 eyes of 140 participants with bilateral large drusen at baseline, seen at 6-monthly intervals up to a 36-month period (from which 40 eyes developed nGA).

Methods

OCT volume and B-scans were labeled for the presence of nGA. Their presence at the volume scan level provided the ground truth for training a deep learning model to identify OCT B-scans that potentially showed nGA requiring manual review. Using a threshold that provided a sensitivity of 0.99, the B-scans identified were assigned the ground truth label with the AI-assisted approach. The performance of this approach for detecting nGA across all visits, or at the visit of nGA onset, was evaluated using fivefold cross-validation.

Main Outcome Measures

Sensitivity for detecting nGA, and proportion of OCT B-scans requiring manual review.

Results

The AI-assisted approach (utilizing outputs from the deep learning model to guide manual review) had a sensitivity of 0.97 (95% confidence interval [CI] = 0.93-1.00) and 0.95 (95% CI = 0.87-1.00) for detecting nGA across all visits and at the visit of nGA onset, respectively, when requiring manual review of only 2.7% and 1.9% of selected OCT B-scans, respectively.

Conclusions

A deep learning model could be used to enable near-perfect detection of nGA onset while reducing the number of OCT B-scans requiring manual review by over 50-fold. This AI-assisted approach shows promise for substantially reducing the current burden of manual review of OCT B-scans to detect this crucial feature that portends future development of GA.

Financial Disclosures

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Utilizing Artificial Intelligence Among Patients With Diabetes: A Systematic Review and Meta-Analysis

Diabetes mellitus, a condition characterized by dysregulation of blood glucose levels, poses significant health challenges globally. This meta-analysis and systematic review aimed to evaluate the effectiveness of artificial intelligence (AI) in managing diabetes, underpinned by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The review scrutinized articles published between January 2019 and February 2024, sourced from six electronic databases: Web of Science, Google Scholar, PubMed, Cochrane Library, EMBASE, and MEDLINE, using keywords such as "Artificial intelligence use in medicine, Diabetes management, Health technology, Machine learning, Diabetic patients, AI applications, and Health informatics." The analysis revealed a notable variance in the prevalence of diabetes symptoms between patients managed with AI models and those receiving standard treatments or other machine learning models, with a risk ratio (RR) of 0.98 (95% CI: 0.88-1.08, I2 = 0%). Sub-group analyses, focusing on symptom detection and management, consistently showed outcomes favoring AI interventions, with RRs of 0.97 (95% CI: 0.87-1.08, I2 = 0%) for symptom detection and 0.97 (95% CI: 0.56-1.57, I2 = 0%) for management, respectively. The findings underscore the potential of AI in enhancing diabetes care, particularly in early disease detection and personalized lifestyle recommendations, addressing the significant health risks associated with diabetes, including increased morbidity and mortality. This study highlights the promising role of AI in revolutionizing diabetes management, advocating for its expanded use in healthcare settings to improve patient outcomes and optimize treatment efficacy.

Extending the diabetic retinopathy screening intervals in Singapore: methodology and preliminary findings of a cohort study

BACKGROUND

The Diabetic Retinopathy Extended Screening Study (DRESS) aims to develop and validate a new DR/diabetic macular edema (DME) risk stratification model in patients with Type 2 diabetes (DM) to identify low-risk groups who can be safely assigned to biennial or triennial screening intervals. We describe the study methodology, participants' baseline characteristics, and preliminary DR progression rates at the first annual follow-up.

METHODS

DRESS is a 3-year ongoing longitudinal study of patients with T2DM and no or mild non-proliferative DR (NPDR, non-referable) who underwent teleophthalmic screening under the Singapore integrated Diabetic Retinopathy Programme (SiDRP) at four SingHealth Polyclinics. Patients with referable DR/DME (> mild NPDR) or ungradable fundus images were excluded. Sociodemographic, lifestyle, medical and clinical information was obtained from medical records and interviewer-administered questionnaires at baseline. These data are extracted from medical records at 12, 24 and 36 months post-enrollment. Baseline descriptive characteristics stratified by DR severity at baseline and rates of progression to referable DR at 12-month follow-up were calculated.

RESULTS

Of 5,840 eligible patients, 78.3% (n = 4,570, median [interquartile range [IQR] age 61.0 [55-67] years; 54.7% male; 68.0% Chinese) completed the baseline assessment. At baseline, 97.4% and 2.6% had none and mild NPDR (worse eye), respectively. Most participants had hypertension (79.2%) and dyslipidemia (92.8%); and almost half were obese (43.4%, BMI ≥ 27.5 kg/m2). Participants without DR (vs mild DR) reported shorter DM duration, and had lower haemoglobin A1c, triglycerides and urine albumin/creatinine ratio (all p < 0.05). To date, we have extracted 41.8% (n = 1909) of the 12-month follow-up data. Of these, 99.7% (n = 1,904) did not progress to referable DR. Those who progressed to referable DR status (0.3%) had no DR at baseline.

CONCLUSIONS

In our prospective study of patients with T2DM and non-referable DR attending polyclinics, we found extremely low annual DR progression rates. These preliminary results suggest that extending screening intervals beyond 12 months may be viable and safe for most participants, although our 3-year follow up data are needed to substantiate this claim and develop the risk stratification model to identify low-risk patients with T2DM who can be assigned biennial or triennial screening intervals.

Economic evaluation for medical artificial intelligence: accuracy vs. cost-effectiveness in a diabetic retinopathy screening case

Artificial intelligence (AI) models have shown great accuracy in health screening. However, for real-world implementation, high accuracy may not guarantee cost-effectiveness. Improving AI's sensitivity finds more high-risk patients but may raise medical costs while increasing specificity reduces unnecessary referrals but may weaken detection capability. To evaluate the trade-off between AI model performance and the long-running cost-effectiveness, we conducted a cost-effectiveness analysis in a nationwide diabetic retinopathy (DR) screening program in China, comprising 251,535 participants with diabetes over 30 years. We tested a validated AI model in 1100 different diagnostic performances (presented as sensitivity/specificity pairs) and modeled annual screening scenarios. The status quo was defined as the scenario with the most accurate AI performance. The incremental cost-effectiveness ratio (ICER) was calculated for other scenarios against the status quo as cost-effectiveness metrics. Compared to the status quo (sensitivity/specificity: 93.3%/87.7%), six scenarios were cost-saving and seven were cost-effective. To achieve cost-saving or cost-effective, the AI model should reach a minimum sensitivity of 88.2% and specificity of 80.4%. The most cost-effective AI model exhibited higher sensitivity (96.3%) and lower specificity (80.4%) than the status quo. In settings with higher DR prevalence and willingness-to-pay levels, the AI needed higher sensitivity for optimal cost-effectiveness. Urban regions and younger patient groups also required higher sensitivity in AI-based screening. In real-world DR screening, the most accurate AI model may not be the most cost-effective. Cost-effectiveness should be independently evaluated, which is most likely to be affected by the AI's sensitivity.

Implementing and evaluating a fully functional AI-enabled model for chronic eye disease screening in a real clinical environment

BACKGROUND

Artificial intelligence (AI) has the potential to increase the affordability and accessibility of eye disease screening, especially with the recent approval of AI-based diabetic retinopathy (DR) screening programs in several countries.

METHODS

This study investigated the performance, feasibility, and user experience of a seamless hardware and software solution for screening chronic eye diseases in a real-world clinical environment in Germany. The solution integrated AI grading for DR, age-related macular degeneration (AMD), and glaucoma, along with specialist auditing and patient referral decision. The study comprised several components: (1) evaluating the entire system solution from recruitment to eye image capture and AI grading for DR, AMD, and glaucoma; (2) comparing specialist's grading results with AI grading results; (3) gathering user feedback on the solution.

RESULTS

A total of 231 patients were recruited, and their consent forms were obtained. The sensitivity, specificity, and area under the curve for DR grading were 100.00%, 80.10%, and 90.00%, respectively. For AMD grading, the values were 90.91%, 78.79%, and 85.00%, and for glaucoma grading, the values were 93.26%, 76.76%, and 85.00%. The analysis of all false positive cases across the three diseases and their comparison with the final referral decisions revealed that only 17 patients were falsely referred among the 231 patients. The efficacy analysis of the system demonstrated the effectiveness of the AI grading process in the study's testing environment. Clinical staff involved in using the system provided positive feedback on the disease screening process, particularly praising the seamless workflow from patient registration to image transmission and obtaining the final result. Results from a questionnaire completed by 12 participants indicated that most found the system easy, quick, and highly satisfactory. The study also revealed room for improvement in the AMD model, suggesting the need to enhance its training data. Furthermore, the performance of the glaucoma model grading could be improved by incorporating additional measures such as intraocular pressure.

CONCLUSIONS

The implementation of the AI-based approach for screening three chronic eye diseases proved effective in real-world settings, earning positive feedback on the usability of the integrated platform from both the screening staff and auditors. The auditing function has proven valuable for obtaining efficient second opinions from experts, pointing to its potential for enhancing remote screening capabilities.

TRIAL REGISTRATION

Institutional Review Board of the Hamburg Medical Chamber (Ethik-Kommission der Ärztekammer Hamburg): 2021-10574-BO-ff.

How Can Artificial Intelligence Be Implemented Effectively in Diabetic Retinopathy Screening in Japan?

Diabetic retinopathy (DR) is a major microvascular complication of diabetes, affecting a substantial portion of diabetic patients worldwide. Timely intervention is pivotal in mitigating the risk of blindness associated with DR, yet early detection remains a challenge due to the absence of early symptoms. Screening programs have emerged as a strategy to address this burden, and this paper delves into the role of artificial intelligence (AI) in advancing DR screening in Japan. There are two pathways for DR screening in Japan: a health screening pathway and a clinical referral path from physicians to ophthalmologists. AI technologies that realize automated image classification by applying deep learning are emerging. These technologies have exhibited substantial promise, achieving sensitivity and specificity levels exceeding 90% in prospective studies. Moreover, we introduce the potential of Generative AI and large language models (LLMs) to transform healthcare delivery, particularly in patient engagement, medical records, and decision support. Considering the use of AI in DR screening in Japan, we propose to follow a seven-step framework for systematic screening and emphasize the importance of integrating AI into a well-designed screening program. Automated scoring systems with AI enhance screening quality, but their effectiveness depends on their integration into the broader screening ecosystem. LLMs emerge as an important tool to fill gaps in the screening process, from personalized invitations to reporting results, facilitating a seamless and efficient system. However, it is essential to address concerns surrounding technical accuracy and governance before full-scale integration into the healthcare system. In conclusion, this review highlights the challenges in the current screening pathway and the potential for AI, particularly LLM, to revolutionize DR screening in Japan. The future direction will depend on leadership from ophthalmologists and stakeholders to address long-standing challenges in DR screening so that all people have access to accessible and effective screening.

Artificial intelligence-supported diabetic retinopathy screening in Tanzania: rationale and design of a randomised controlled trial

INTRODUCTION

Globally, diabetic retinopathy (DR) is a major cause of blindness. Sub-Saharan Africa is projected to see the largest proportionate increase in the number of people living with diabetes over the next two decades. Screening for DR is recommended to prevent sight loss; however, in many low and middle-income countries, because of a lack of specialist eye care staff, current screening services for DR are not optimal. The use of artificial intelligence (AI) for DR screening, which automates the grading of retinal photographs and provides a point-of-screening result, offers an innovative potential solution to improve DR screening in Tanzania.

METHODS AND ANALYSIS

We will test the hypothesis that AI-supported DR screening increases the proportion of persons with true referable DR who attend the central ophthalmology clinic following referral after screening in a single-masked, parallel group, individually randomised controlled trial. Participants (2364) will be randomised (1:1 ratio) to either AI-supported or the standard of care DR screening pathway. Participants allocated to the AI-supported screening pathway will receive their result followed by point-of-screening counselling immediately after retinal image capture. Participants in the standard of care arm will receive their result and counselling by phone once the retinal images have been graded in the usual way (typically after 2-4 weeks). The primary outcome is the proportion of persons with true referable DR attending the central ophthalmology clinic within 8 weeks of screening. Secondary outcomes, by trial arm, include the proportion of persons attending the central ophthalmology clinic out of all those referred, sensitivity and specificity, number of false positive referrals, acceptability and fidelity of AI-supported screening.

ETHICS AND DISSEMINATION

The London School of Hygiene & Tropical Medicine, Kilimanjaro Christian Medical Centre and Tanzanian National Institute of Medical Research ethics committees have approved the trial. The results will be submitted to peer-reviewed journals for publication.

TRIAL REGISTRATION NUMBER

ISRCTN18317152.

Artificial intelligence, ChatGPT, and other large language models for social determinants of health: Current state and future directions

This perspective highlights the importance of addressing social determinants of health (SDOH) in patient health outcomes and health inequity, a global problem exacerbated by the COVID-19 pandemic. We provide a broad discussion on current developments in digital health and artificial intelligence (AI), including large language models (LLMs), as transformative tools in addressing SDOH factors, offering new capabilities for disease surveillance and patient care. Simultaneously, we bring attention to challenges, such as data standardization, infrastructure limitations, digital literacy, and algorithmic bias, that could hinder equitable access to AI benefits. For LLMs, we highlight potential unique challenges and risks including environmental impact, unfair labor practices, inadvertent disinformation or "hallucinations," proliferation of bias, and infringement of copyrights. We propose the need for a multitiered approach to digital inclusion as an SDOH and the development of ethical and responsible AI practice frameworks globally and provide suggestions on bridging the gap from development to implementation of equitable AI technologies.

Exploring the Impact of Artificial Intelligence on Global Health and Enhancing Healthcare in Developing Nations

BACKGROUND

Artificial intelligence (AI), which combines computer science with extensive datasets, seeks to mimic human-like intelligence. Subsets of AI are being applied in almost all fields of medicine and surgery.

AIM

This review focuses on the applications of AI in healthcare settings in developing countries, designed to underscore its significance by comprehensively outlining the advancements made thus far, the shortcomings encountered in AI applications, the present status of AI integration, persistent challenges, and innovative strategies to surmount them.

METHODOLOGY

Articles from PubMed, Google Scholar, and Cochrane were searched from 2000 to 2023 with keywords including AI and healthcare, focusing on multiple medical specialties.

RESULTS

The increasing role of AI in diagnosis, prognosis prediction, and patient management, as well as hospital management and community healthcare, has made the overall healthcare system more efficient, especially in the high patient load setups and resource-limited areas of developing countries where patient care is often compromised. However, challenges, including low adoption rates and the absence of standardized guidelines, high installation and maintenance costs of equipment, poor transportation and connectivvity issues hinder AI's full use in healthcare.

CONCLUSION

Despite these challenges, AI holds a promising future in healthcare. Adequate knowledge and expertise of healthcare professionals for the use of AI technology in healthcare is imperative in developing nations.

Multi-scale multi-attention network for diabetic retinopathy grading

Objective.Diabetic retinopathy (DR) grading plays an important role in clinical diagnosis. However, automatic grading of DR is challenging due to the presence of intra-class variation and small lesions. On the one hand, deep features learned by convolutional neural networks often lose valid information about these small lesions. On the other hand, the great variability of lesion features, including differences in type and quantity, can exhibit considerable divergence even among fundus images of the same grade. To address these issues, we propose a novel multi-scale multi-attention network (MMNet).Approach.Firstly, to focus on different lesion features of fundus images, we propose a lesion attention module, which aims to encode multiple different lesion attention feature maps by combining channel attention and spatial attention, thus extracting global feature information and preserving diverse lesion features. Secondly, we propose a multi-scale feature fusion module to learn more feature information for small lesion regions, which combines complementary relationships between different convolutional layers to capture more detailed feature information. Furthermore, we introduce a Cross-layer Consistency Constraint Loss to overcome semantic differences between multi-scale features.Main results.The proposed MMNet obtains a high accuracy of 86.4% and a high kappa score of 88.4% for multi-class DR grading tasks on the EyePACS dataset, while 98.6% AUC, 95.3% accuracy, 92.7% recall, 95.0% precision, and 93.3% F1-score for referral and non-referral classification on the Messidor-1 dataset. Extensive experiments on two challenging benchmarks demonstrate that our MMNet achieves significant improvements and outperforms other state-of-the-art DR grading methods.Significance.MMNet has improved the diagnostic efficiency and accuracy of diabetes retinopathy and promoted the application of computer-aided medical diagnosis in DR screening.

Robotics and AI in the Global South

An increasing presence of robotics and artificial intelligence in the Global South calls for responsible implementation.